We are live on ! Find out more
HEPA

Hepion Pharmaceuticals
HEPA

Delisted

HEPA was delisted on the 12th of May, 2025.

Back to rankings

3 hedge funds and large institutions have $9.09M invested in Hepion Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

34% more capital invested

Capital invested by funds: $6.79M → $9.09M (+$2.3M)

0% more funds holding

Funds holding: 3 → 3 (0)

Holders
3
Holders Change
–
Holders Change %
0%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Nomura Holdings
Nomura Holdings
Japan
-$17K
2
EWA
Exencial Wealth Advisors
Oklahoma
-$10K
3
UBS Group
UBS Group
Switzerland
-$5K

HEPA Hedge Fund Activity: Q3 2016 in Review

3 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q3 2016, worth a combined $9.09M — up 34% from $6.79M a quarter earlier.

Fund positioning in HEPA was balanced in Q3 2016: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

The largest seller was Nomura Holdings, cutting an estimated $17K.

  • 3 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q3 2016, unchanged from Q2 2016.
  • Funds reported $9.09M of Hepion Pharmaceuticals stock for Q3 2016, up 34% quarter-over-quarter.
  • 0 funds opened new Hepion Pharmaceuticals positions in Q3 2016 and 0 closed out.
  • The largest Hepion Pharmaceuticals seller in Q3 2016 was Nomura Holdings, an estimated $17K sold.

Based on aggregated 13F filings for Q3 2016.